AGTC to Present at the H.C. Wainwright Global Investment Conference
May 18 2022 - 8:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical
stage biotechnology company focused on the development of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare and debilitating diseases with an initial focus on
inherited retinal diseases (IRDs), today announced that Sue Washer,
President & Chief Executive Officer, Jon Lieber, Chief
Financial Officer, and Susan Schneider, Chief Medical Officer, will
be presenting virtually at the H.C. Wainwright Global Investment
Conference held May 23 - 26, 2022.
The presentation will be available to view
on-demand beginning Tuesday, May 24 at 7:00 a.m. ET through the
entirety of the conference and available by visiting
http://ir.agtc.com/events-and-presentations.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies with the
potential to address unmet patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with inherited retinal
diseases. AGTC has active clinical trials in X-linked retinitis
pigmentosa (XLRP) and achromatopsia (ACHM CNGB3). Its preclinical
programs build on the company’s industry leading AAV manufacturing
technology and scientific expertise. AGTC is advancing multiple
important pipeline candidates to address substantial unmet clinical
needs in optogenetics, otology and CNS disorders, and has entered
strategic collaborations with companies including Bionic Sight, an
innovator in the emerging field of optogenetics, and retinal coding
and Otonomy, Inc., a biopharmaceutical company dedicated to the
development of innovative therapeutics for neurotology. For more
information, please visit https://agtc.com/.
IR/PR Contacts:David
Carey (IR)Lazar FINN PartnersT: (212)
867-1768david.carey@finnpartners.com
Corporate Contact:Jonathan
LieberChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5778jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024